Balancing the risk of major bleeding against vascular disease risk in people without atherosclerotic disease
The derived models using routinely available disease history and laboratory measurements improved distinction of the MVE-to-MB ratio compared with using conventional models for MB risk including vascular risk factors. Such models can help identify those with moderate MVE risk but low MB risk who may benefit from low-dose aspirin.
Authors
- Jane Armitage (ORCID: https://orcid.org/0000-0001-8691-9226)
- Colin Baigent (ORCID: https://orcid.org/0000-0003-4856-7420)
- Jonathan Emberson (ORCID: https://orcid.org/0000-0001-7792-9422)
- Sarah Parish (ORCID: https://orcid.org/0000-0003-3532-0832)
- Marion Mafham (ORCID: https://orcid.org/0000-0003-0562-3963)
- Alison Offer (ORCID: https://orcid.org/0000-0002-3367-3207)
- Jemma C. Hopewell (ORCID: https://orcid.org/0000-0002-3870-8018)
- Imen Hammami (ORCID: https://orcid.org/0009-0006-7874-1070)
Institutions
- University of Oxford (GB)
Publication Details
- Journal
- Heart
- Published
- 2025-02-26
- DOI
- https://doi.org/10.1136/heartjnl-2024-324841
- Citations
- 1
- Primary Topic
- Antiplatelet Therapy and Cardiovascular Diseases
- Type
- article
- Field-Weighted Citation Impact
- 1.39
Funders
- Novartis
- British Heart Foundation
- Novo Nordisk
- BHF Centre of Research Excellence, Oxford
- Medical Research Council
- NIHR Oxford Biomedical Research Centre